$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000155905316000084 Filed on November 02, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$171.0K	$286.0K	$429.0K
YoY Change	-44.3%	-33.33%	-71.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.600M	$16.14M	$5.910M
YoY Change	44.8%	173.1%	39.72%
% of Gross Profit
Research & Development	$39.84M	$26.84M	$17.19M
YoY Change	122.69%	56.17%	65.43%
% of Gross Profit
Depreciation & Amortization	$920.0K	$800.0K	$200.0K
YoY Change	318.18%	300.0%	0.0%
% of Gross Profit
Operating Expenses	$49.45M	$42.97M	$23.09M
YoY Change	101.67%	86.12%	57.96%
Operating Profit		-$42.69M	-$22.66M
YoY Change		88.38%	72.56%
Interest Expense	$150.0K	$140.0K	$50.00K
YoY Change	87.5%	180.0%	150.0%
% of Operating Profit
Other Income/Expense, Net	$580.0K	-$130.0K	-$77.00K
YoY Change	-3000.0%	68.83%	-140.31%
Pretax Income	-$48.55M	-$42.82M	-$22.74M
YoY Change	100.95%	88.31%	75.71%
Income Tax	$350.0K	$421.0K	$238.0K
% Of Pretax Income
Net Earnings	-$48.90M	-$43.24M	-$22.98M
YoY Change	102.44%	88.19%	74.3%
Net Earnings / Revenue	-28598.25%	-15118.53%	-5355.71%
Basic Earnings Per Share	-$1.41	-$1.26	-$0.73
Diluted Earnings Per Share	-$1.41	-$1.26	-$0.73
COMMON SHARES
Basic Shares Outstanding	34.49M shares	34.40M shares	31.44M shares
Diluted Shares Outstanding			31.44M shares

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$386.9M	$408.6M	$387.8M
YoY Change	4.4%	5.36%	26.65%
Cash & Equivalents	$386.9M	$408.6M	$387.8M
Short-Term Investments
Other Short-Term Assets	$4.300M	$6.700M	$5.000M
YoY Change	-31.75%	34.0%	212.5%
Inventory
Prepaid Expenses
Receivables	$178.0K	$409.0K	$814.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$391.4M	$415.6M	$393.6M
YoY Change	3.7%	5.61%	27.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$56.45M	$51.74M	$2.930M
YoY Change	1361.73%	1665.8%	-10.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.193M	$2.162M	$7.000K
YoY Change	95.63%	30785.71%	-99.53%
Total Long-Term Assets	$68.61M	$63.94M	$5.354M
YoY Change	775.96%	1094.32%	12.06%
TOTAL ASSETS
Total Short-Term Assets	$391.4M	$415.6M	$393.6M
Total Long-Term Assets	$68.61M	$63.94M	$5.354M
Total Assets	$460.0M	$479.6M	$398.9M
YoY Change	19.4%	20.22%	27.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.07M	$10.54M	$4.058M
YoY Change	189.2%	159.73%	227.26%
Accrued Expenses	$25.70M	$22.60M	$13.00M
YoY Change	54.82%	73.85%	85.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$41.08M	$36.91M	$18.56M
YoY Change	84.89%	98.88%	86.12%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$126.0K
YoY Change	-100.0%	-100.0%	-94.0%
Total Long-Term Liabilities	$53.50M	$41.57M	$2.419M
YoY Change	2175.54%	1618.64%	17.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.08M	$36.91M	$18.56M
Total Long-Term Liabilities	$53.50M	$41.57M	$2.419M
Total Liabilities	$94.57M	$78.48M	$20.98M
YoY Change	284.96%	274.13%	74.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$289.2M	-$240.3M	-$104.9M
YoY Change	124.02%	128.98%	196.62%
Common Stock	$348.0K	$344.0K	$315.0K
YoY Change	9.78%	9.21%	14.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$365.4M	$401.1M	$378.0M
YoY Change
Total Liabilities & Shareholders Equity	$460.0M	$479.6M	$398.9M
YoY Change	19.4%	20.22%	27.21%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$48.90M	-$43.24M	-$22.98M
YoY Change	102.44%	88.19%	74.3%
Depreciation, Depletion And Amortization	$920.0K	$800.0K	$200.0K
YoY Change	318.18%	300.0%	0.0%
Cash From Operating Activities	-$33.81M	-$29.76M	-$16.91M
YoY Change	71.71%	75.99%	37.82%
INVESTING ACTIVITIES
Capital Expenditures	-$7.140M	-$8.560M	-$330.0K
YoY Change	628.57%	2493.94%	200.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.060M
YoY Change
Cash From Investing Activities	-$7.140M	-$4.500M	-$330.0K
YoY Change	628.57%	1263.64%	200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.30M	3.950M	2.650M
YoY Change	459.42%	49.06%	-81.95%
NET CHANGE
Cash From Operating Activities	-33.81M	-29.76M	-16.91M
Cash From Investing Activities	-7.140M	-4.500M	-330.0K
Cash From Financing Activities	19.30M	3.950M	2.650M
Net Change In Cash	-21.65M	-30.31M	-14.59M
YoY Change	25.73%	107.75%	-734.35%
FREE CASH FLOW
Cash From Operating Activities	-$33.81M	-$29.76M	-$16.91M
Capital Expenditures	-$7.140M	-$8.560M	-$330.0K
Free Cash Flow	-$26.67M	-$21.20M	-$16.58M
YoY Change	42.54%	27.86%	36.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	4077000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34488428	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
	dei	Trading Symbol TradingSymbol	PRTA
	prta	Accrued Offering Costs AccruedOfferingCosts	12000	USD
	prta	Accrued Offering Costs AccruedOfferingCosts	0	USD
CY2015Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	12794000	USD
CY2016Q3	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	16937000	USD
CY2015Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	0	USD
CY2016Q3	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	39358000	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	0	USD
	prta	Capitalized Interestunder Buildto Suit Transaction CapitalizedInterestunderBuildtoSuitTransaction	713000	USD
CY2015Q3	prta	Collaboration Revenue CollaborationRevenue	429000	USD
	prta	Collaboration Revenue CollaborationRevenue	1300000	USD
CY2016Q3	prta	Collaboration Revenue CollaborationRevenue	286000	USD
	prta	Collaboration Revenue CollaborationRevenue	884000	USD
CY2015Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2016Q3	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2015Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2016Q3	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2015Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2016Q3	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2015Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2016Q3	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2015Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2016Q3	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2016Q3	prta	Future Minimum Sublease Rentals FutureMinimumSubleaseRentals	447000	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Thereafter FutureMinimumSubleaseRentalsThereafter	0	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Year Five FutureMinimumSubleaseRentalsYearFive	0	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Year Four FutureMinimumSubleaseRentalsYearFour	0	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Year One FutureMinimumSubleaseRentalsYearOne	131000	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Year Three FutureMinimumSubleaseRentalsYearThree	0	USD
CY2016Q3	prta	Future Minimum Sublease Rentals Year Two FutureMinimumSubleaseRentalsYearTwo	316000	USD
CY2015Q1	prta	Gain Losson Sublease GainLossonSublease	-400000	USD
	prta	Gain Losson Sublease Noncash Portion GainLossonSubleaseNoncashPortion	-261000	USD
	prta	Gain Losson Sublease Noncash Portion GainLossonSubleaseNoncashPortion	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	0	USD
	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	550000	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	0	USD
	prta	Noncash Investingand Financing Items Stock Option Shortfall NoncashInvestingandFinancingItemsStockOptionShortfall	18000	USD
	prta	Noncashamountcapitalizedunderbuildtosuittransaction Noncashamountcapitalizedunderbuildtosuittransaction	38584000	USD
	prta	Numberof Votes NumberofVotes	1	vote
	prta	Operating Leases Annual Rent Payment OperatingLeasesAnnualRentPayment	2100000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	960000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Due For Remainderof Year PurchaseandContractualObligationDueForRemainderofYear	21357000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	132000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	189000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	274000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	237000	USD
CY2016Q3	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	23149000	USD
	prta	Receivable Stock Option Exercises ReceivableStockOptionExercises	0	USD
	prta	Receivable Stock Option Exercises ReceivableStockOptionExercises	76000	USD
CY2015Q1	prta	Sublease Leases Optional Extension Term SubleaseLeasesOptionalExtensionTerm	P1Y
CY2015Q1	prta	Sublease Leases Term SubleaseLeasesTerm	P3Y
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4519000	USD
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10540000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	509000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	409000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2016Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1180000	USD
CY2015Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2016Q3	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	98000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	325000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	819000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5343000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6844000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	489455000	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	641064000	USD
CY2016Q3	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	50400	sqft
CY2015Q4	us-gaap	Assets Assets	385236000	USD
CY2016Q3	us-gaap	Assets Assets	479582000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	377403000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	415638000	USD
CY2015Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	7833000	USD
CY2016Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	63944000	USD
CY2015Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	167000	USD
CY2016Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	313000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293579000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	387802000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	370586000	USD
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31744102	shares
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	408574000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	94223000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	37988000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34456309	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31744102	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34456309	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	317000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	344000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	USD
CY2016Q3	us-gaap	Construction In Progress Gross ConstructionInProgressGross	47409000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-704000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3156000	USD
CY2015Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	284000	USD
CY2016Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	336000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2127000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2118000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	2850000	USD
CY2016Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	5988000	USD
CY2015Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	600000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	800000	USD
	us-gaap	Depreciation Depreciation	1500000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	588000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1509000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.89
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.25
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3774000	USD
CY2016Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5615000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2351000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	827000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	2351000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	827000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5905000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16476000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16136000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31452000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-22738000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-55756000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-42818000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-110414000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	238000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	699000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	421000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	791000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	442000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1557000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7502000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11004000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-915000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-100000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-30000	USD
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-304000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	964000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	4056000	USD
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	50000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	116000	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	138000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	405000	USD
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2020-11-30
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2828000	USD
CY2016Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2770000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	24567000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	78482000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	385236000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	479582000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22216000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	36908000	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2351000	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	41574000	USD
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6210000	USD
CY2016Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	8090000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137394000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134812000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-397000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13553000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42774000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83271000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-22976000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-56455000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-43239000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-111205000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
	us-gaap	Operating Expenses OperatingExpenses	111142000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-31000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-130000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-156000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	23090000	USD
	us-gaap	Operating Expenses OperatingExpenses	57025000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	42974000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22661000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55725000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42688000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-110258000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	10913000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	552000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2289000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2412000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2328000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2249000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1083000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1121000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2162000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4903000	USD
CY2016Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8251000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	126000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-127000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-147000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-268000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-561000	USD
CY2015Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	520000	USD
CY2016Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1481000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	0	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-2812000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	397000	USD
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	9497000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6308000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6655000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131481000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	128777000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3562000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2396000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9205000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	58582000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3862000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51738000	USD
CY2016Q3	us-gaap	Purchase Obligation PurchaseObligation	21559000	USD
CY2016Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2016Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	32000	USD
CY2016Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	59000	USD
CY2016Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	144000	USD
CY2016Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	107000	USD
CY2016Q3	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	21217000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17185000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40549000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26838000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79690000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129103000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-240308000	USD
CY2015Q3	us-gaap	Revenues Revenues	429000	USD
	us-gaap	Revenues Revenues	1300000	USD
CY2016Q3	us-gaap	Revenues Revenues	286000	USD
	us-gaap	Revenues Revenues	884000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	3017000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7136000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	11448000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19718000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1850000	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	360669000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	401100000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31441000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29893000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34413000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34266000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2015 are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. Credit risk exposure is up to the extent of amounts recorded on the Company's Condensed Consolidated Balance Sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$51.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> were held in Ireland. </font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, storage, testing or distribution of preclinical or clinical supplies of any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, store, test and distribute all preclinical development and clinical supplies of its drug candidates, and the Company plans to continue to do so for the foreseeable future. Currently, the Company has a single source of preclinical or clinical supplies for each of its drug candidates. A delay or inability to obtain such supply could have an adverse effect on the Company's business, financial condition and results of operations.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-16-000084-index-headers.html	Edgar Link	pending
0001559053-16-000084-index.html	Edgar Link	pending
0001559053-16-000084.txt	Edgar Link	pending
0001559053-16-000084-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prta-20160930.xml	Edgar Link	completed
prta-20160930.xsd	Edgar Link	pending
prta-20160930_cal.xml	Edgar Link	unprocessable
prta-20160930_def.xml	Edgar Link	unprocessable
prta-20160930_lab.xml	Edgar Link	unprocessable
prta-20160930_pre.xml	Edgar Link	unprocessable
prta2016q310-q.htm	Edgar Link	pending
prta2016q310-qxex311.htm	Edgar Link	pending
prta2016q310-qxex312.htm	Edgar Link	pending
prta2016q310-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2016 Q4 Form 10-Q Financial Statement

#000155905316000084 Filed on November 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2016 Q4 Form 10-Q Financial Statement

#000155905316000084 Filed on November 02, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta